Every day, Global University Venturing rounds up investments from across the university innovation ecosystem in its deal net.

ProVerum, an Ireland-based benign prostatic hyperplasia therapy spinout from Trinity College Dublin, secured €30m ($34m) in a series A round yesterday. The round was co-led by Gilde Healthcare Partners and Lightstone Ventures, with commitments from unnamed existing backers. The spinout had raised $4.2m in a seed round involving University Bridge Fund, the spinout-focused venture fund…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.